trending Market Intelligence /marketintelligence/en/news-insights/trending/_gYBJveV3LKRD1AuJqx4mA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Edwards Lifesciences invests in 2 privately held heart disease focused companies

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Edwards Lifesciences invests in 2 privately held heart disease focused companies

Edwards Lifesciences Corp. said it invested $35 million to gain an exclusive right to buy privately held Corvia Medical Inc., which makes implants to treat heart failure.

Tewksbury, Mass.-based Corvia's InterAtrial Shunt Device is approved in the European Union to treat heart failure with preserved or mildly reduced ejection fraction.

The device is undergoing clinical trials in the U.S. to seek approval from the U.S. Food and Drug Administration.

Irvine, Calif.-based Edwards Lifesciences also acquired certain assets of Mitralign Inc. including intellectual property and associated clinical and regulatory experience.

Tewksbury, Mass.-based Mitralign makes devices to treat functional mitral and tricuspid regurgitation, which are diseases resulting from dysfunctional valves within the heart.

Edwards Lifesciences, which is focused on making medical devices for heart diseases, did not disclose additional terms of the transactions.

The company added that the transactions are not expected to impact its 2019 financial guidance.